Advisor Group’s Neurogene NGNE Stock Holding History

Advisor Group’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10	Closed	-$3K	–	5030
2017 Q3	$3K	Hold	10	–	–	﹤0.01%	4432
2017 Q2	$3K	Buy	+10	New	+$2.86K	﹤0.01%	4419

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Advisor Group's NGNE Position: Q4 2017 in Review

Advisor Group sold out of Neurogene (NGNE) in Q4 2017, closing a stake of 10 shares — an estimated $3K sold.

Advisor Group first reported a position in NGNE in Q2 2017 and held it in 2 quarters. The position peaked at $3K in Q3 2017. 52 funds tracked by Wall St. Rank hold NGNE as of Q4 2017.

Advisor Group reported no remaining Neurogene position as of Q4 2017 after selling out during the quarter.
Advisor Group sold 10 Neurogene shares in Q4 2017, an estimated $3K.
Advisor Group first reported a position in Neurogene in Q2 2017 and held it in 2 quarters.
Advisor Group's Neurogene position peaked at $3K in Q3 2017.
52 funds tracked by Wall St. Rank held Neurogene as of Q4 2017.

Based on Advisor Group's 13F filing for Q4 2017, filed 14 Feb 2018.